PL
RAPT

Portman Ltd’s RAPT Therapeutics RAPT Stock Holding History

Portman Ltd’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$307K Buy
+1,596
New +$302K 0.54% 5

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Portman Ltd's RAPT Position: Q3 2022 in Review

Portman Ltd opened a new position in RAPT Therapeutics (RAPT) in Q3 2022: 1,596 shares worth $307K. The stake represents 0.54% of the portfolio and ranks #5 among its holdings.

98 funds tracked by Wall St. Rank hold RAPT as of Q3 2022.

  • Portman Ltd held 1,596 shares of RAPT Therapeutics worth $307K as of Q3 2022.
  • RAPT Therapeutics was a new Portman Ltd position in Q3 2022.
  • RAPT Therapeutics made up 0.54% of Portman Ltd's portfolio in Q3 2022, its #5 holding.
  • 98 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2022.

Based on Portman Ltd's 13F filing for Q3 2022, filed 14 Nov 2022.